With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology | GenomeWeb

Roughly one year after securing €5 million ($6.5 million) in venture capital funding, Spanish oligonucleotide drug developer nLife Therapeutics has set its sights on initiating non-human primate testing of its core intranasal delivery technology, which it hopes will spur licensing deals with bigger industry players, according to the firm's top executive.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.